

| | | | |
|---|--|---------------------|-------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50120/008001 |
| <p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> | | Serial No. | 10/585,772 |
| | | Applicant | Young et al. |
| | | Filing Date | November 13, 2007 |
| | | Group | 1635 |
| (37 C.F.R. § 1.98(b)) | | IDS Filed | May 25, 2010 |

| U.S. PATENT DOCUMENTS | | | |
|-----------------------|-----------------|--------------------|-----------------------|
| Examiner's Initials | Document Number | Publication Date | Patentee or Applicant |
| | 2003/0175950 | September 18, 2003 | McSwiggen |
| | 2004/0006035 | January 8, 2004 | Macejak et al. |
| | 2004/0068763 | April 8, 2004 | Hopkins et al. |
| | 2005/0255487 | November 17, 2005 | Khvorova et al. |
| | 2006/0241070 | October 26, 2006 | Wright |
| | 2008/0255085 | October 16, 2008 | Young et al. |
| | 12/691,664 | N/A | |
| | 12/700,563 | N/A | |

| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION | | | | |
|--|-----------------|-------------------|--------------------------|----------------------|
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Translation (Yes/No) |
| | WO 03/099298 | December 4, 2003 | WIPO | |
| | WO 04/070033 | August 19, 2004 | WIPO | |
| | WO 05/065719 | July 21, 2005 | WIPO | |
| | WO 06/017932 | February 23, 2006 | WIPO | |

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | |
|---|---|
| | Agrawal and Kandimalla, Antisense and/or immunostimulatory oligonucleotide therapeutics, Curr Cancer Drug Targets. 2001 Nov;1(3):197-209. |
| | Björklund et al., Structure and promoter characterization of the gene encoding the large subunit (R1 protein) of mouse ribonucleotide reductase, Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11322-6. |
| | Duxbury et al., Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer, Surgery. 2004 Aug;136(2):261-9. |

| | |
|---|----------------------------|
| EXAMINER /Dana Shin/ | DATE CONSIDERED 08/23/2010 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

| | | | |
|---|--|---------------------|-------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50120/008001 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Serial No. | 10/585,772 |
| | | Applicant | Young et al. |
| | | Filing Date | November 13, 2007 |
| | | Group | 1635 |
| (37 C.F.R. § 1.98(b)) | | IDS Filed | May 25, 2010 |

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | |
|---|---|
| | GenBank Entry ay032750, "Homo sapiens ribonucleotide reductase M2 subunit (RRM2) gene, complete cds." (May 12, 2001), National Center for Biotechnology Information, Bethesda, MD. |
| | GenBank Entry BC001886, "Homo sapiens ribonucleotide reductase M2 polypeptide, mRNA (cDNA clone MGC:1551 IMAGE:3528619), complete cds." (January 29, 2001), National Center for Biotechnology Information, Bethesda, MD. |
| | International Search Report for PCT/CA2004/00175, mailed May 7, 2004. |
| | International Search Report for PCT/CA2005/00040, mailed June 7, 2005. |
| | International Search Report for PCT/CA2005/001258, mailed January 3, 2006. |
| | Lee et al., GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors, Cancer Res. 2003 Jun 1;63(11):2802-11. |
| | Lepoivre et al., Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells, J Biol Chem. 1990 Aug 25;265(24):14143-9. |
| | Lin et al., Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors, J Biol Chem. 2004 Jun 25;279(26):27030-8. Epub 2004 Apr 19. |
| | Mader et al., Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro, Biochem Pharmacol. 1997 Dec 1;54(11):1233-42. |
| | Office Action (U.S. Application No. 10/545,152), mailed September 21, 2009. |
| | Office Action (U.S. Application No. 11/573,879), mailed September 29, 2008. |
| | Office Action (U.S. Application No. 11/573,879), mailed February 13, 2009. |
| | Office Action (U.S. Application No. 11/573,879), mailed November 5, 2009. |
| | Orr, Technology evaluation: leukemia therapy, University of Pennsylvania, Curr Opin Mol Ther. 1999 Jun;1(3):399-403. |
| | Pavloff et al., Sequence analysis of the large and small subunits of human ribonucleotide reductase, DNA Seq. 1992;2(4):227-34. |
| | Vose et al., Update on epidemiology and therapeutics for non-Hodgkin's lymphoma, Hematology Am Soc Hematol Educ Program. 2002:241-62. |

| | |
|---|----------------------------|
| EXAMINER /Dana Shin/ | DATE CONSIDERED 08/23/2010 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/